Stem Cell Research
1. Adipose stromal vascular fraction-mediated improvements at late-stage disease in a murine model of multiple sclerosis.
Stem Cells. 2016 Oct 12. doi: 10.1002/stem.2516. [Epub ahead of print]
Bowles AC, Strong AL, Wise RM, Thomas RC, Gerstein BY, Dutreil MF, Hunter RS, Gimble JM, Bunnell BA
Adam Stepien, Natalia L. Dabrowska, Marzena Maciagowska, Renata Piusinska Macoch, Aleksandra Zolocinska, Slawomir Mazur,Katarzyna Siennicka,Emilia Frankowska, Rafał Kidzinski, Małgorzata Chalimoniuk, and Zygmunt Pojda
According to the National MS Society, multiple sclerosis is an unpredictable, disabling disease that affects the central nervous system that disrupts the flow of information within the brain and between the brain and body. As of yet, scientist have been unable to identify the causes for MS, the most that is known is that unidentified environmental factor in a person genetically predisposed to respond triggers the disease. Worldwide, more than 2.3 million people are affected by MS. At this time MS cannot be cured, although some advances in medicine have slowed down the progression of the disease.
Stem cells, which are the mainstream tool in regenerative medicine are being studied as a possible therapy to ameliorate the symptoms and slow the progression of the disease. The need to find a cure, or at least some relief to the people who suffer from this disease have fueled the research in cell based therapies to find promising results. The use of the stromal vascular fraction, which is the current treatment we offer at SCHI, has demonstrated better results than purified and laboratory cultivated adipose derived stem cells. So far the procedures have been deemed safe and without adverse side effects. The mode of application is through intrathecal injection or mannitol supplemented IV.